Jordan J. S. VerPlank et al. discovered that cGMP, through PKG, stimulates 26 S proteasomes and augments the degradation of proteins, including those responsible for neurodegenerative diseases, indicating that compounds that elevate cGMP levels could potentially slow the progression of neurodegenerative diseases by stimulating cytosolic proteasomes, protein ubiquitination, and overall protein degradation [85]. The gene discussed is PRKG1; the disease is neurodegenerative disease.